DE69630120D1 - Kristalle von fragmenten von cd40-liganden und deren verwendung - Google Patents

Kristalle von fragmenten von cd40-liganden und deren verwendung

Info

Publication number
DE69630120D1
DE69630120D1 DE69630120T DE69630120T DE69630120D1 DE 69630120 D1 DE69630120 D1 DE 69630120D1 DE 69630120 T DE69630120 T DE 69630120T DE 69630120 T DE69630120 T DE 69630120T DE 69630120 D1 DE69630120 D1 DE 69630120D1
Authority
DE
Germany
Prior art keywords
crystals
fragments
ligands
ligand
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69630120T
Other languages
English (en)
Other versions
DE69630120T2 (de
Inventor
Mihail N Karpusas
Juswinder Singh
David W Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DE69630120D1 publication Critical patent/DE69630120D1/de
Publication of DE69630120T2 publication Critical patent/DE69630120T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
DE69630120T 1995-06-22 1996-06-21 Kristalle von fragmenten von cd40-liganden und deren verwendung Expired - Fee Related DE69630120T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44895P 1995-06-22 1995-06-22
US448P 1995-06-22
PCT/US1996/010664 WO1997000895A1 (en) 1995-06-22 1996-06-21 Crystals of fragments of cd40 ligand and their use

Publications (2)

Publication Number Publication Date
DE69630120D1 true DE69630120D1 (de) 2003-10-30
DE69630120T2 DE69630120T2 (de) 2004-04-08

Family

ID=21691579

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630120T Expired - Fee Related DE69630120T2 (de) 1995-06-22 1996-06-21 Kristalle von fragmenten von cd40-liganden und deren verwendung

Country Status (11)

Country Link
EP (1) EP0833847B1 (de)
JP (2) JPH11508262A (de)
AT (1) ATE250630T1 (de)
AU (1) AU6337296A (de)
CA (1) CA2224812A1 (de)
DE (1) DE69630120T2 (de)
DK (1) DK0833847T3 (de)
ES (1) ES2202455T3 (de)
HK (1) HK1010085A1 (de)
PT (1) PT833847E (de)
WO (1) WO1997000895A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834228A (en) * 1997-02-13 1998-11-10 Merck & Co., Inc. Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex
EP1754490A3 (de) 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD154-Blockadetherapie der Pankreasinselzellentransplantation bei Primaten
ID27933A (id) 1998-05-12 2001-05-03 Warner Lambert Co Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
PL374181A1 (en) 2001-02-09 2005-10-03 Genentech, Inc. Crystallization of igf-1
WO2013036829A1 (en) 2011-09-09 2013-03-14 Genentech, Inc Treatment of th17 mediated inflammatory diseases
CN112151122A (zh) * 2020-09-10 2020-12-29 国家纳米科学中心 结构未知晶体衍射能力的计算方法及物相定量分析方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2121798C (en) * 1991-10-25 2007-07-24 Richard J. Armitage Novel cytokine
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
AU677995B2 (en) * 1993-01-22 1997-05-15 Immunex Corporation Detection and treatment of mutations in a CD40 ligand gene

Also Published As

Publication number Publication date
PT833847E (pt) 2004-02-27
EP0833847A1 (de) 1998-04-08
EP0833847B1 (de) 2003-09-24
ATE250630T1 (de) 2003-10-15
DK0833847T3 (da) 2003-12-29
CA2224812A1 (en) 1997-01-09
HK1010085A1 (en) 1999-06-11
JP2006188541A (ja) 2006-07-20
ES2202455T3 (es) 2004-04-01
DE69630120T2 (de) 2004-04-08
WO1997000895A1 (en) 1997-01-09
AU6337296A (en) 1997-01-22
JPH11508262A (ja) 1999-07-21

Similar Documents

Publication Publication Date Title
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE60035204D1 (de) Tyrosinderivate
IL143747A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
DE69433406D1 (de) Antikörper gegen cd40
CY1105395T1 (el) Αναστολη της raf κινασης χρησιμοποιωντας αρυλικες και ετepοαρυλικες υποκατεστημενες ετepοκυκλικες ουριες
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
NO891940L (no) Fremgangsmaate for selektivt aa redusere permeabiliteten avoljefrie soner i underjordiske formasjoner.
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
ATE388399T1 (de) Verwendung von hroralpha rezeptoren zur auffindung von anti-atherosclerotischen verbindungen
DE69630120D1 (de) Kristalle von fragmenten von cd40-liganden und deren verwendung
DE60306672D1 (de) Verwendung von metallkomplexverbindungen als oxidationskatalysatoren
TR200003606T2 (tr) Yüksek çinko oluşumlu yeni insülin benzerleri.
DE69841687D1 (de) Erythrovirus und ihre verwendung
YU36104A (sh) Kristalna struktura fosfodiesteraza 5 i njihova upotreba
DE69940971D1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
ATE434936T1 (de) Tsg101-gag-wechselwirkung und ihre verwendung
ES2124727T3 (es) Silicio de grano fino con halogeno unido superficialmente, procedimiento para su preparacion y su uso.
DE69326349T2 (de) Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
DE69938343D1 (de) 13-hydroperoxide lyase von guave (psidium guajava) sowie dessen verwendung
DE69711422T2 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
NO971325L (no) Fremgangsmåte for fremstilling av 3,4-dihydroksy-5-nitrobenzaldehyd
FR2768730B1 (fr) Procede de photostabilisation du 4-(ter.butyl) 4'-methoxy dibenzoylmethane, compositions filtrantes ainsi obtenues et leurs utilisations
DE69912306D1 (de) 1,4-diaryl-2-fluor-1-buten-3-ol-verbindungen und ihre verwendung in der herstellung von 1,4-diaryl-2-fluor-1,3-butadien- und 1,4-diaryl-2-fluor-2-buten-verbindungen
DE60204800D1 (de) Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose
UA29225A (uk) Спосіб прогнозування ефективності комплексної терапії гострих обструктивних бронхітів у дітей

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US

8339 Ceased/non-payment of the annual fee